SELLAS Life Sciences Group Inc. Common Stock (SLS)
Stock · NASDAQ · Health Care
$9.98as of 10/16/2026
Price chart
Active signals
SLS Signal Track Record
How signals performed across all stocks →What SLS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -0.7% | 48% | September 11, 2026 |
| Bollinger Band Breakout | 30 | -1.0% | 47% | August 19, 2026 |
| Bollinger Band BreakdownActive now | 16 | +4.3% | 63% | September 11, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +8.3% | 70% | November 28, 2025 |
| Any 20-session window (baseline) | +2.3% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It h…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 13
- Website
- www.sellaslifesciences.com/
Fundamentals
- 1-day range
- $9.75$11.24
- Market cap
- $2.18B
- P/E (trailing)
- —
- P/E (forward)
- -99.80
- EPS (trailing)
- $-0.22
- Dividend yield
- —
- Beta
- 2.68
- Avg. volume
- 6.37M
- Dividend pay date
- November 8, 2019
How SELLAS Life Sciences Group Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 16, 2023 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
SELLAS Life Sciences Group Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SLSSELLAS Life Sciences Group Inc. Common Stock$9.98▼ 11.99%Market cap $2.18BP/E —$1.39$15.88
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SLS SELLAS Life Sciences Group Inc. Common Stock | $2.18B | — | $9.98 | ▼ 11.99% | $1.39$15.88 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Banking Bellwethers Kick Off Earnings, Fed Chair's Speech In FocusSeekingAlpha · 10/10/2026
- SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal HopesYahoo · 10/8/2026
- SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 SpotYahoo · 10/2/2026
- SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027Yahoo · 10/1/2026
- Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3Yahoo · 10/1/2026
- Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?Yahoo · 10/1/2026
- SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer DataYahoo · 9/30/2026
- SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic DataYahoo · 9/30/2026
- SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Modelsbenzinga · 9/25/2026
Insider Activity
Insider Actions →- Stergiou Angelos M. · June 16, 2026 · Grant1.06M
Institutional Ownership
March 31, 2026
- Total shares held
- 66.74M
- Total value held
- $278.72M
- Institutional holders
- 158
- Unknown12.20M
- Unknown8.98M
- Unknown8.40M
- Unknown7.53M
- Unknown4.88M
- Unknown3.91M
- Unknown2.04M
- Unknown1.68M
- Unknown1.34M
- Unknown1.28M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study
SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.